Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials.

"Declarations Ethics approvalThe TENAYA and LUCERNE trials were conducted in accordance with the International Council for Harmonisation E6 Guideline for Good Clinical Practice; tenets of the Declaration of Helsinki; applicable US Food and Drug Administration regulations and the European Union Clinical Trials Directive (2001/20/EC); and relevant local, state, and federal laws. Study protocols were approved by institutional review boards and ethics committees as applicable. Consent to participateWritten informed consent was obtained from all patients in the TENAYA and LUCERNE trials. Consent to publishNot applicable. Competing interestsKT has received rewards from Bayer, Chugai Pharmaceutical Co., Ltd, Kyowa Kirin, Novartis Pharma, Santen, and Senju. CMGC is a consultant for Allergan, Bayer, Boehringer Ingelheim, Novartis, Roche, Samsung, and Topcon. TI is a consultant for Bayer, Boehringer Ingelheim, Chugai Pharmaceutical Co., Ltd/Roche, Novartis, and Senju. TYYL receives research support from Bayer, Novartis, and Roche and is a consultant for Alcon, Allergan, Bayer, Boehringer Ingelheim, Novartis, Oculis, and Roche. MO receives speaking fees from Chugai Pharmaceutical Co., Ltd. YY receives financial support from Alcon Japan, Sanbio, and Santen Pharmaceuticals and speaking fees from Chugai Pharmaceutical Co., Ltd. MK, SO, and TS are employees of Chugai Pharmaceutical Co., Ltd. AK and VP are employees of Roche Products Ltd. HL is an employee of Genentech, Inc. BS is an employee of F. Hoffman-La Roche Ltd. WKL is a consultant for Bayer, Novartis, and Roche. Competing interests KT has received rewards from Bayer, Chugai Pharmaceutical Co., Ltd, Kyowa Kirin, Novartis Pharma, Santen, and Senju. CMGC is a consultant for Allergan, Bayer, Boehringer Ingelheim, Novartis, Roche, Samsung, and Topcon. TI is a consultant for Bayer, Boehringer Ingelheim, Chugai Pharmaceutical Co., Ltd/Roche, Novartis, and Senju. TYYL receives research support from Bayer, Novartis, and Roche and is a consultant for Alcon, Allergan, Bayer, Boehringer Ingelheim, Novartis, Oculis, and Roche. MO receives speaking fees from Chugai Pharmaceutical Co., Ltd. YY receives financial support from Alcon Japan, Sanbio, and Santen Pharmaceuticals and speaking fees from Chugai Pharmaceutical Co., Ltd. MK, SO, and TS are employees of Chugai Pharmaceutical Co., Ltd. AK and VP are employees of Roche Products Ltd. HL is an employee of Genentech, Inc. BS is an employee of F. Hoffman-La Roche Ltd. WKL is a consultant for Bayer, Novartis, and Roche."

"Funding F. Hoffmann-La Roche Ltd. (Basel, Switzerland), Genentech, Inc. (South San Francisco, California, USA), and Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan) provided financial support for the study. Funding was provided by Chugai Pharmaceutical Co., Ltd. for third-party writing assistance, which was provided by Ellen M. Ross, PhD, of Envision Pharma Group."

"Trial registration ClinicalTrials.gov identifier: NCT03823287 (TENAYA); NCT03823300 (LUCERNE). Date of registration: January 30, 2019. "